



1 July 2020

Mr Corey Lian  
Adviser, ASX Listings Compliance (Sydney)  
ASX Compliance Pty Ltd  
Exchange Centre  
20 Bridge Street  
SYDNEY NSW 2000

By email: [ListingsComplianceSydney@asx.com.au](mailto:ListingsComplianceSydney@asx.com.au)

Dear Corey

#### **ASX PRICE QUERY**

We refer to the Price Query from the ASX dated 1 July 2020 in relation to the change in price of ACW's securities from a low of \$0.022 to a high of \$0.035 today, and respond as follows to the specific questions asked:

- 1. Is ACW aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?**

No. The Company is not aware of any information concerning it that has not been announced, which, if known by some in the market, could explain the recent trading in its securities.

**If the answer to question 1 is "yes":**

- (a) Is ACW relying on Listing Rule 3.1A not to announce under Listing Rule 3.1?**
- (b) Can an announcement be made immediately?**
- (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?**

The answer to question 1 is no – therefore not applicable.

- 2. If the answer to question 1 is "no", is there any other explanation that ACW may have for the recent trading in its securities?**

The Company is aware that Alterity Therapeutics (ASX:ATH), a biotech company undertaking biomedical research in a broadly similar area to Actinogen, released an announcement on the ASX on 30 June 2020 that appeared to generate a >1500% increase in the ATH share-price today. We speculate that the increase in Actinogen's share-price may have been as a direct consequence of this.

The Company is not aware of any other explanation for the recent trading in its securities.


**3. Please confirm that ACW is in compliance with the listing rules and, in particular, listing rule 3.1.**

We confirm that the Company is in compliance with the Listing Rules and, in particular, Listing Rule 3.1.

**4. Please confirm that ACW's responses to the questions above have been authorised and approved in accordance with its published continuous disclosure policy or otherwise by its board or an officer of the Company with delegated authority from the board to respond to the ASX on disclosure matters.**

Confirmed.

Yours sincerely



**Peter Webse**

Company Secretary


**Actinogen Medical**

Dr. Bill Ketelbey

CEO & Managing Director

P: +61 2 8964 7401

E: bill.ketelbey@actinogen.com.au

 @BillKetelbey

**Investor Enquiries**

Miranda Newnham

Vesparum Capital

P: +61 3 8582 4800

E: actinogen@vesparum.com

***Authorised by the Board of Directors of Actinogen Medical***

**About Actinogen Medical**

Actinogen Medical (ASX: ACW) is an ASX-listed biotechnology company developing innovative treatments for cognitive impairment associated with chronic neurological, psychiatric and metabolic diseases. The company is currently developing its lead compound Xanamem as a promising new therapy for Alzheimer's disease, and cognitive impairment associated with schizophrenia, diabetes and other disorders associated with cognitive impairment. The cognitive dysfunction associated with these conditions is significantly debilitating for patients, and there is a substantial unmet medical need for new and improved treatments.

**About Xanamem™**

Xanamem is Actinogen Medical's lead developmental drug candidate. Xanamem's novel mechanism of action sets it apart from other therapies for Alzheimer's disease and other diseases associated with cognitive impairment. It works by blocking the excess production of intracellular cortisol – the stress hormone – through the inhibition of the 11β-HSD1 enzyme in the brain. There is a strong association between persistent stress and the production of excess cortisol that leads to changes in the brain, affecting memory. The 11β-HSD1 enzyme is highly concentrated in the hippocampus and frontal cortex, the areas of the brain associated with cognitive impairment in neurological diseases, including Alzheimer's disease and schizophrenia and in metabolic diseases like diabetes.

The Company's XanaHES Phase I trial exploring the safety and tolerability of Xanamem 20mg once daily in healthy elderly volunteers, showed that the drug exhibited a good safety profile with no treatment-related serious adverse events. Additionally, the trial demonstrated that Xanamem produced a statistically significant

improvement in cognition, which, along with other recently generated data, confirms the underlying mechanism of action of Xanamem.

The Company plans to initiate Phase II studies of Xanamem against various diseases as soon as possible after the current COVID19 health crisis affecting the globe; including in Mild Cognitive Impairment due to Alzheimer's disease.

Xanamem is an investigational product and is not approved for use outside of a clinical trial by the FDA or by any global regulatory authority.

Xanamem™ is a trademark of Actinogen Medical

#### **Disclaimer**

This announcement and attachments may contain certain forward-looking statements that are based on subjective estimates and assumptions and relate to circumstances and events that have not taken place and may not take place. Such forward looking statements involve known and unknown risks, uncertainties, and other factors (such as significant business, economic and competitive uncertainties and contingencies) which may cause the actual results or the performance of Actinogen Medical to be materially different from the results or performance expressed or implied by such forward looking statements. Past performance is not a reliable indicator of future performance. There can be no assurance that any forward-looking statements will be realised. Actinogen Medical does not make any representation or give any warranty as to the likelihood of achievement or reasonableness of any forward-looking statements.

**Actinogen Medical encourages all current investors to go paperless by registering their details with the designated registry service provider, Link Market Services.**



1 July 2020

Reference: 20040

Mr Peter Webse  
Company Secretary  
Actinogen Medical Limited

Dear Mr Webse

### **Actinogen Medical Limited ('ACW'): Price Query**

We note the change in the price of ACW's securities from a low of \$0.022 to a low of \$0.035 today.

We also note the significant increase in the volume of ACW's securities traded today.

### **Request for Information**

In light of this, ASX asks ACW to respond separately to each of the following questions and requests for information:

1. Is ACW aware of any information concerning it that has not been announced to the market which, if known by some in the market, could explain the recent trading in its securities?
2. If the answer to question 1 is "yes".
  - (a) Is ACW relying on Listing Rule 3.1A not to announce that information under Listing Rule 3.1? Please note that the recent trading in ACW's securities would suggest to ASX that such information may have ceased to be confidential and therefore ACW may no longer be able to rely on Listing Rule 3.1A. Accordingly, if the answer to this question is "yes", you need to contact us immediately to discuss the situation.
  - (b) Can an announcement be made immediately? Please note, if the answer to this question is "no", you need to contact us immediately to discuss requesting a trading halt (see below).
  - (c) If an announcement cannot be made immediately, why not and when is it expected that an announcement will be made?
3. If the answer to question 1 is "no", is there any other explanation that ACW may have for the recent trading in its securities?
4. Please confirm that ACW is complying with the Listing Rules and, in particular, Listing Rule 3.1.
5. Please confirm that ACW's responses to the questions above have been authorised and approved under its published continuous disclosure policy or otherwise by its board or an officer of ACW with delegated authority from the board to respond to ASX on disclosure matters.

### **When and where to send your response**

This request is made under Listing Rule 18.7. Your response is required as soon as reasonably possible and, in any event, by no later than **5:00 PM AEST today Wednesday, 1 July 2020**. If we do not have your response by then, ASX will likely suspend trading in ACW's securities under Listing Rule 17.3. You should note that if the information requested by this letter is information required to be given to ASX under Listing Rule 3.1 and it does not fall within the exceptions mentioned in Listing Rule 3.1A, ACW's obligation is to disclose the information "immediately". This may require the information to be disclosed before the deadline set out in the previous paragraph.

---

ASX reserves the right to release a copy of this letter and your response on the ASX Market Announcements Platform under Listing Rule 18.7A. Accordingly, your response should be in a form suitable for release to the market. Your response should be sent to me by e-mail at [ListingsComplianceSydney@asx.com.au](mailto:ListingsComplianceSydney@asx.com.au). It should not be sent directly to the ASX Market Announcements Office. This is to allow me to review your response to confirm that it is in a form appropriate for release to the market, before it is published on the ASX Market Announcements Platform.

### **Listing Rules 3.1 and 3.1A**

Listing Rule 3.1 requires a listed entity to give ASX immediately any information concerning it that a reasonable person would expect to have a material effect on the price or value of the entity's securities. Exceptions to this requirement are set out in Listing Rule 3.1A. In responding to this letter, you should have regard to ACW's obligations under Listing Rules 3.1 and 3.1A and also to *Guidance Note 8 Continuous Disclosure: Listing Rules 3.1 – 3.1B*. It should be noted that ACW's obligation to disclose information under Listing Rule 3.1 is not confined to, nor is it necessarily satisfied by, answering the questions set out in this letter.

### **Trading halt**

If you are unable to respond to this letter by the time specified above, or if the answer to question 1 is "yes" and an announcement cannot be made immediately, you should discuss with us whether it is appropriate to request a trading halt in ACW's securities under Listing Rule 17.1. If you wish a trading halt, you must tell us:

- the reasons for the trading halt;
- how long you want the trading halt to last;
- the event you expect to happen that will end the trading halt;
- that you are not aware of any reason why the trading halt should not be granted; and
- any other information necessary to inform the market about the trading halt, or that we ask for.

We may require the request for a trading halt to be in writing. The trading halt cannot extend past the commencement of normal trading on the second day after the day on which it is granted.

You can find further information about trading halts in *Guidance Note 16 Trading Halts & Voluntary Suspensions*.

### **Suspension**

If you are unable to respond to this letter by the time specified above ASX will likely suspend trading in ACW's securities under Listing Rule 17.3.

### **Release of correspondence between ASX and entity**

We reserve the right to release a copy of this letter, your reply and any other related correspondence between us to the market under listing rule 18.7A.

### **Enquiries**

If you have any queries or concerns about any of the above, please contact me immediately

Regards

---

**Corey Lian**  
Adviser, Listings Compliance (Sydney)